Europe Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), and End User (Hospitals, Oncology Clinics, Research Centers, and Others)

The Europe lung cancer therapy market was valued at US$9.91 billion in 2022 and is expected to reach US$25.54 billion by 2030; it is estimated to grow at a CAGR of 12.6% from 2022 to 2030.

Government Initiatives for Screening and Treatment of Lung Cancer Drive Europe Lung Cancer Therapy Market

According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer. The Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients. Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the Europe lung cancer therapy market.

Europe Lung Cancer Therapy Market Overview

According to an article titled "Lung Cancer in Germany," published in the Journal of Thoracic Oncology in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. With an age-standardized incidence rate of 52.1% and 32.7% (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly.

The German National Cancer Plan designates organ cancer centers (lung cancer centers), oncology centers, and comprehensive cancer centers to offer general oncologic care in Germany. As of 2020, 64 lung cancer centers at 79 institutions were certified nationwide. Rise in the incidence of lung cancer and an increase in the number of lung cancer centers across Germany are fueling the growth of the market.

Europe Lung Cancer Therapy Market Segmentation

The Europe lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the Europe lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Europe lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the Europe lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the Europe lung cancer therapy market is segmented into Germany, the UK, France, Italy, Spain, Russia, and the Rest of Europe. Germany dominated the Europe lung cancer therapy market in 2022.

Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the Europe lung cancer therapy market.